This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership

06/29/15 - 05:10 PM EDT

Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.

read more >

Other Articles by Adam

Free Reports

Avalanche Fails Common-Sense Test, Kicked Out of Gene Therapy Credibility Club

06/16/15 - 06:53 AM EDT

I wanted to slam my forehead against the desk after the Avalanche CEO repeated for the 600th time, 'The key takeaway today is that it's a positive study.'

read more >
Agios Blood Cancer Drugs Are Fine -- It's the Analysis That's Causing Confusion

06/15/15 - 12:03 PM EDT

Agios shares are falling because investors thought the performance of its cancer drugs fell short, but only the method used to calculate response changed.

read more >
Bluebird Sickle Cell Gene Therapy Results Keep Getting Better

06/13/15 - 05:32 AM EDT

Six months after infusion with the Bluebird gene therapy known as LentiGlobin, almost half of the oxygen-carrying red blood cells in a single patient are normal and functioning.

read more >
Agios 'Cancer Metabolism' Drugs Induce Prolonged Responses in Blood Cancer Patients

06/12/15 - 05:55 AM EDT

Updated results from two early-stage studies of Agios' AG-221 and AG-110 are being presented at a European medical meeting.

read more >
Advisory Panel Recommends Bluebird Delay Gene Therapy Clinical Trial

06/09/15 - 08:18 PM EDT

The company's CEO said that Bluebird's plans had not changed despite a government panel's recommendation to delay the start of the trial until more data is gathered.

read more >
Diabetes Docs Wary of MannKind's Afrezza Insulin, Analyst Survey Finds

06/09/15 - 09:08 AM EDT

Jefferies analyst gives excellent lesson in how to spin something positive from a negative MannKind survey when investment banking calls.

read more >
Inside the Hedge Fund Club Pitching a New Alzheimer's Drug IPO

06/08/15 - 02:34 PM EDT

The Axovant Sciences IPO, scheduled for this week, is one of those clubby hedge-fund deals which explains why most investors believe Wall Street is an unfair game.

read more >
Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle

06/08/15 - 07:01 AM EDT

Titan and its partner will resubmit Probuphine for FDA approval later this year.

read more >
Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind

06/05/15 - 05:02 AM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Top-Performing Biotech and Drug Stocks During ASCO '15

06/04/15 - 07:49 AM EDT

Between May 12 and June 3, Oncothyreon's stock price rose 183%, best among all the companies presenting cancer drug research at the American Society of Clinical Oncology annual meeting.

read more >
Page 2 of 337
Top Rated Stocks Top Rated Funds Top Rated ETFs